What were the key takeaways from the Imricor Medical Systems (ASX:IMR) FY25 results?

Imricor reported a transformative year defined by major regulatory wins and clinical milestones rather than immediate revenue growth. Key achievements included receiving European CE Mark approval for its second-generation platform and subsequent FDA clearance for the NorthStar mapping system in January.

Is Imricor Medical Systems (ASX:IMR) profitable yet?

No, Imricor is not yet profitable and remains in a high-growth, capital-intensive phase typical of medical technology companies. For FY25, the company reported revenue of US$292,000, which management attributed to a temporary dip as customers prioritised clinical trial enrolments over equipment purchases. While revenue is currently low, the company maintains a strong liquidity cushion with US$40.8 million in cash and marketable securities to fund ongoing operations.

What does the FDA clearance of the NorthStar system mean for IMR shareholders?

The FDA clearance of the NorthStar 3D mapping system and the Vision-MR Diagnostic Catheter is a major de-risking event for the investment thesis. It allows Imricor to begin marketing its MRI-native guidance technology in the US, the world’s largest healthcare market.

How did Imricor (ASX:IMR) perform clinically during the 2025 financial year?

Imricor achieved several world-firsts, most notably performing the first-in-human ischemic ventricular tachycardia (VT) ablation under real-time MRI guidance in Amsterdam. The company also successfully completed pre-clinical trials for Pulsed Field Ablation (PFA) under MRI guidance, a high-growth area in cardiac electrophysiology.

What is Imricor’s commercial strategy for the European market?

The company spent FY25 building the infrastructure necessary for a commercial scale-up by completing the hiring and training of a dedicated European sales team. This investment appears to be gaining early traction, with the customer pipeline growing nearly sixfold from 7 to 40 potential sites by the end of the year.

What are the main bull and bear points for Imricor (ASX:IMR) after this news?

The bull case rests on Imricor’s first-mover advantage as the only provider of MRI-native 3D mapping, backed by a strong US$40.8 million cash balance and fresh FDA/CE Mark approvals. The bear case centres on the very low current revenue.

Health

Image for illustrative purposes only. Not a real photo.

Imricor achieves regulatory and global commercial milestones

Written by Heidi Cuthbert Published Feb 25, 2026, 4:40 AMLast Updated Jul 6, 2026, 10:45 AM

Imricor Medical Systems (ASX:IMR) announced its financial and operational results for the full year 2025, highlighting a pivotal period of regulatory achievements and global commercial expansion.

A primary highlight was receiving CE Mark approval under the EU Medical Device Regulation for its second-generation platform, which includes the Vision-MR Ablation Catheter and the NorthStar 3D mapping and guidance system—the first of its kind to be MRI-native.

Following this, the NorthStar system and Vision-MR Diagnostic Catheter also received FDA clearance in January.

Clinically, the company achieved a landmark milestone by performing the first-in-human ischemic ventricular tachycardia ablation under real-time MRI guidance at Amsterdam University Medical Centre.

Imricor also expanded its US presence, adding the University of Virginia, Virginia Commonwealth University, and Oklahoma Heart Institute to its VISABL-AFL clinical trial.

Furthermore, the company successfully completed the world’s first pre-clinical in vivo pulsed field ablation under real-time MRI guidance.

Imricor bolstered its European infrastructure by completing the hiring and training of its sales team, while its customer pipeline surged from 7 to 40 by year-end.

Expansion into the Middle East is also underway, with two iCMR labs currently under construction in Saudi Arabia.

The company reported US$292,000 in revenue, noting a temporary impact as customers focused on clinical trial enrolments.

Imricor concluded the year with a solid liquidity position, holding US$40.8 million in cash and marketable securities as of Dec. 31, 2025.

At the time of reporting, Imricor Medical Systems’ share price was $1.96.

Imricor achieves regulatory and global commercial milestones

Frequently asked questions

Assets related to this article